Financial giants have made a conspicuous bullish move on Merck & Co. Our analysis of options history for Merck & Co MRK revealed 12 unusual trades.
Delving into the details, we found 58% of traders were bullish, while 41% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $1,400,107, and 8 were calls, valued at $1,381,750.
What's The Price Target?
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $120.0 to $135.0 for Merck & Co over the recent three months.
Volume & Open Interest Development
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Merck & Co's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Merck & Co's significant trades, within a strike price range of $120.0 to $135.0, over the past month.
Merck & Co Option Activity Analysis: Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| MRK | CALL | TRADE | BULLISH | 01/17/25 | $125.00 | $1.0M | 2.8K | 1.0K |
| MRK | PUT | TRADE | BEARISH | 01/16/26 | $135.00 | $951.0K | 1 | 601 |
| MRK | PUT | TRADE | BULLISH | 01/17/25 | $125.00 | $382.5K | 1.6K | 524 |
| MRK | CALL | SWEEP | BEARISH | 04/05/24 | $127.00 | $79.3K | 183 | 757 |
| MRK | CALL | SWEEP | BULLISH | 04/19/24 | $125.00 | $62.0K | 15.7K | 695 |
About Merck & Co
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
In light of the recent options history for Merck & Co, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Current Position of Merck & Co
- Trading volume stands at 4,597,764, with MRK's price up by 0.01%, positioned at $123.86.
- RSI indicators show the stock to be is currently neutral between overbought and oversold.
- Earnings announcement expected in 31 days.
What The Experts Say On Merck & Co
3 market experts have recently issued ratings for this stock, with a consensus target price of $124.66666666666667.
- An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $135.
- An analyst from Societe Generale downgraded its action to Sell with a price target of $104.
- In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $135.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Merck & Co with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
